{"id":454861,"date":"2021-03-10T09:18:10","date_gmt":"2021-03-10T14:18:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454861"},"modified":"2021-03-10T09:18:10","modified_gmt":"2021-03-10T14:18:10","slug":"apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/","title":{"rendered":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Data published in <em>Ophthalmology <\/em>and the <em>American Journal of Ophthalmology<\/em> underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy<\/li>\n<\/ul>\n<p>WALTHAM, Mass., March  10, 2021  (GLOBE NEWSWIRE) &#8212; \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gblrEH9FxG7hHir25fhh82MYnS3SsBBh9QY5N_TODdyRbuvr75lHOPQGh3M9_TGfbY9voh7OJPc8B7Sw_nCmh4iw6M4By_9bmznGCbV1rxsCs05oMLnYnp8lX3b8KDte4lJgn3p17CpWYy3LxiWR2PIe4znaIG-U8lDU-1iJzep8_0UW-Bzatq13BqRyYZkTE-YM9Em1q9Zj06BZkFtbCpP2VmCdU6uqRFRxzz12y4rbJ7vUTViA0LF_OkmdPpDuhOUBYqDoqH6BfSGDUTY3OA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Apellis Pharmaceuticals<\/u><\/a>,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leading journals, <em>Ophthalmology<\/em> and the <em>American Journal of Ophthalmology<\/em>, published post hoc analyses from the Phase 2 FILLY study of intravitreal pegcetacoplan for geographic atrophy (GA) secondary to AMD. GA is a leading cause of blindness that affects approximately five million people around the world<sup>1,2<\/sup> and has no approved treatments.<\/p>\n<ul type=\"disc\">\n<li>The analysis, \u201cImpact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan,\u201d was published in the <a href=\"https:\/\/www.ajo.com\/article\/S0002-9394(21)00096-9\/fulltext\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><em>American Journal of Ophthalmology<\/em><\/a>, and showed that efficacy results across patient subgroups were consistent with the FILLY results.\n<\/li>\n<li>Published in <a href=\"https:\/\/www.aaojournal.org\/article\/S0161-6420(21)00163-9\/fulltext\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><em>Ophthalmology<\/em><\/a>, \u201cCharacterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy,\u201d further clarified characteristics of investigator-determined exudations reported in the study.<\/li>\n<\/ul>\n<p>\u201cGeographic atrophy remains the most significant unmet need in the retina, and we are committed to advancing the first medicine for people living with this relentless disease,\u201d said Federico Grossi, M.D., Ph.D., chief medical officer of Apellis. \u201cThese data from two new analyses of our positive Phase 2 FILLY study reinforce the potential of pegcetacoplan in GA, and we look forward to sharing results from our Phase 3 GA studies in the third quarter of this year.\u201d<\/p>\n<p>Pegcetacoplan is currently being evaluated in two pivotal studies, DERBY and OAKS, which enrolled more than 1,200 patients with GA.<\/p>\n<p>\n        <strong>About Pegcetacoplan (APL-2)<\/strong><br \/>\n        <br \/> Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body\u2019s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Pegcetacoplan is being evaluated in several clinical studies across hematology, ophthalmology, nephrology, and neurology. Marketing applications for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) are under review by the U.S. Food and Drug Administration (FDA), which has granted the application Priority Review designation, and the European Medicines Agency (EMA). Pegcetacoplan was granted Fast Track designation by the FDA for the treatment of geographic atrophy and received orphan drug designation for the treatment of C3G by the FDA and EMA. For additional information regarding pegcetacoplan clinical trials, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NuAVvTIY94CxOvw09YiA_qDawJSjNCqvT0hfeHQvAm6Ta44AFgp2IEeofWB5J5CmmjsJn6QrzlExMudCzi3wyFDeTcC0AZ9uywt__SUm8Zww1_u2SxbG6AgdoOPty4bbziixAP8d47n9GtDyq_bsPTRGBeXLtDIVw0KWlcqL50fe8_Dg1Vyz-xnaafDvzheeu40sfhC5eWA4OT0lvzCw6d5PwPqKaP6m3jZoFE1d-Vc6kzNJM9S9WNstx5MEaLGetXvgKNNsMUXK1_QT-l4ZYr5TeZYhhNfKMoTXgEpf4j_ThnmOwdMWrdgtv8ZSg5f1-0hAGEZsRnbUF2u3OwlaCyLbcJsbaAdjETstM8hc2CQGAVAOWKwoHp3qqVVZYj9c\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/apellis.com\/our-science\/clinical-trials<\/a>.<\/p>\n<p>\n        <strong>About Geographic Atrophy (GA)<\/strong>\u00a0<br \/>GA is an advanced form of age-related macular degeneration (AMD), a leading cause of blindness. GA lesions affect the central portion of the retina, known as the macula, which is responsible for central vision. Excessive complement activation drives irreversible lesion growth in GA<sup>3<\/sup>, and C3 is the only target to precisely control complement overactivation. GA is progressive and irreversible, leading to central visual impairment and permanent loss of vision. Based on published studies, approximately one million people have GA in\u00a0the United States and 5 million people have GA globally.<sup>1,2<\/sup>\u00a0There are currently no\u00a0approved treatments for GA.<\/p>\n<p>\n        <strong>About FILLY<\/strong><br \/>\n        <br \/>The FILLY study was a 246-patient, Phase 2, multicenter, randomized, single-masked, sham-controlled clinical trial evaluating pegcetacoplan in patients with GA secondary to AMD conducted at over 40 clinical sites in the United States, Australia, and New Zealand. Pegcetacoplan was administered as an intravitreal injection monthly or every other month (EOM) for 12 months, followed by six months of monitoring after the end of treatment. The primary efficacy endpoint was the change in GA lesion area from baseline to Month 12 in pegcetacoplan-treated patients compared to sham.<\/p>\n<p>\n        <strong>About DERBY and OAKS<\/strong><br \/>\n        <br \/>DERBY (621 patients enrolled) and OAKS (638 patients enrolled) are Phase 3, multicenter, randomized, double-masked, sham-controlled studies comparing the efficacy and safety of intravitreal pegcetacoplan with sham injections in patients with GA secondary to AMD. The primary objective of the studies is to evaluate the efficacy of pegcetacoplan in patients with GA assessed by change in the total area of GA lesions from baseline as measured by fundus autofluorescence.<\/p>\n<p>\n        <strong>About Apellis<\/strong>\u00a0<br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2XusSkESD5WvlC97QTWsijAjNEzuA85dNSINhNmOjGvXynN1y4vMWvXMlBmHyYSSxmZxWBwSJ6mwjjJH4ofUh5wESiMeBx1imRjgrVQ28B6xlvs4yElnZj__-TTNE_tizmjGzg-KdjB5-8kaeTxSydsOpzuGiR9u56uegYcIU23IR-zJOlqA4m2VGwJ-Mrt6ABTm8GxuA4h4wbP0NVK64SOE8lDmvXTiNrkNWfl5E0s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.apellis.com<\/a>.<\/p>\n<p>\n        <strong>Apellis Forward-Looking Statement<\/strong>\u00a0<br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the closing of the exchanges will be satisfied and other factors discussed in the \u201cRisk Factors\u201d section of Apellis\u2019 Annual Report on Form 10-K filed with the\u00a0Securities and Exchange Commission\u00a0on February 25, 2021\u00a0and the risks described in other filings that Apellis may make with the\u00a0Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Mark Dole<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QIHRgIXPqYxAFdTicTFrvKEsGVdwHF_PreaBtUPNwsXT8ZNhLbBEELinXmTI51pYClErnc6Q-inJ7A55c0tFZLYj_8pQ8JYigah2bnx-GN4olL7ky7baEtKuDH2J_UwjVJefF7hsPHxAasI6x7MA3F3DQ4L6lOY4HF50YQ-DNbiMy7CXwkiSc9dJwvsYp_R405CsCHfyjaRURV3ShmDgLpaiYOLFXsTc81yohxdfOns=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@apellis.com<\/a><br \/>617.997.3484<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>apellis@argotpartners.com\u00a0<br \/>212.600.1902\u00a0<\/p>\n<p>1 Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. <em>Ophthalmology<\/em> 2012;119:571\u2013580.<\/p>\n<p>2 Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. <em>Lancet Glob Health<\/em> 2014;2:e106\u2013116.<\/p>\n<p>3 Seddon, JM, Rosner, B. Validated prediction models for macular degeneration progression and predictors of visual acuity loss identify high-risk individuals. <em>Am J Ophthalmol<\/em> 2019;198:223\u2013261.\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f4ecd3dd-72d5-4f67-979f-ec2e8ce2cf00\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leading journals, Ophthalmology and the American Journal of Ophthalmology, published post hoc analyses from the Phase 2 FILLY study of intravitreal pegcetacoplan for geographic atrophy (GA) secondary to AMD. GA is a leading cause of blindness that affects approximately five million people around the world1,2 and has no approved treatments. The analysis, \u201cImpact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan,\u201d was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454861","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leading journals, Ophthalmology and the American Journal of Ophthalmology, published post hoc analyses from the Phase 2 FILLY study of intravitreal pegcetacoplan for geographic atrophy (GA) secondary to AMD. GA is a leading cause of blindness that affects approximately five million people around the world1,2 and has no approved treatments. The analysis, \u201cImpact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan,\u201d was &hellip; Continue reading &quot;Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T14:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy\",\"datePublished\":\"2021-03-10T14:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/\"},\"wordCount\":1051,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/\",\"name\":\"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\",\"datePublished\":\"2021-03-10T14:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk","og_description":"Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leading journals, Ophthalmology and the American Journal of Ophthalmology, published post hoc analyses from the Phase 2 FILLY study of intravitreal pegcetacoplan for geographic atrophy (GA) secondary to AMD. GA is a leading cause of blindness that affects approximately five million people around the world1,2 and has no approved treatments. The analysis, \u201cImpact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan,\u201d was &hellip; Continue reading \"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T14:18:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy","datePublished":"2021-03-10T14:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/"},"wordCount":1051,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/","name":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=","datePublished":"2021-03-10T14:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzczMCM0MDU3NjMyIzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pegcetacoplan-in-geographic-atrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454861"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454861\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}